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Introduction
Vitamin K antagonists (VKAs) are routinely prescribed for the treatment and prevention of thromboembolic events with more than 22 million prescriptions issued for warfarin in the USA annually. 1 In clinical practice in the USA, major hemorrhage in VKA-treated patients reportedly occurs at an annual rate of 1.7 to 3.4%. 2 Furthermore, there are >60,000 annual emergency department visits for hemorrhagic complications in VKA-treated patients. 3 Bleeding and elevated International Normalized Ratio (INR) are also common manifestations of adverse drug events in older adults, accounting for ~42,000 hospitalizations annually in the USA. 4 Patients presenting with acute hemorrhage require rapid VKA reversal via prompt restoration of vitamin K-dependent coagulation factors (VKDF). 5 The first step is the administration of vitamin K; however, reversal can take several hours therefore it is not recommended as monotherapy for acute bleeding. 5, 6 VKDF replacement can be achieved by administering plasma or prothrombin complex concentrate (PCC). 7, 8, 9 Despite widespread usage, the efficacy of plasma for urgent VKA reversal has not been established and it has several drawbacks including: 1) time delays for ABO blood-typing and thawing of frozen plasma; 2) large volumes and long infusion times to reach the factor levels necessary to correct coagulopathy; 3) risk of pathogen transmission; 4) risk of transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO), leading causes of transfusion-related deaths. [7] [8] [9] [10] An alternative to plasma is PCC. There are two types of PCCs: activated (licensed for treatment of hemophilia A or B with an inhibitor) and non-activated. Non-activated PCCs are lyophilized concentrates of VKDFs, referred to as 3-factor (contain significant quantities of FII, presenting with acute hemorrhage require rapid VKA reversal via prompt restora ra at t tion on o o o of f f vi vi vita ta tam mi min K-dependent coagulation factors (VKDF). 5 The first step is the administration of vitamin K; ho ow we weve ve ver r, r r rev ev e e ersa sa al l l ca can take several hours therefor or ore e i i it is not recomm mm men nde de ded d d as monotherapy for ac cut ut te e bleeding g. 5, 5,6 5,6 VK VK KDF DF DF r re e epl la lace ce eme m ment n c can an a b b be e e a ac achi hi iev ev ved ed ed by y y ad ad dm mi mini ni ist t ter er erin in ing g g pl pl p a as asma ma ma o o or p pr prot ot othr hr rom om ombi bi bin n c c com mp mple le ex x concentrate (P (P (PCC CC C ). ). ) 7 8 FIX, and FX) or 4-factor (4F; also contain sufficient FVII). 7, 11 PCCs can be promptly administered due to their relatively small infusion volume and because there is no need for thawing or blood-type matching. 7 PCCs are effective for urgent VKA reversal 12 and are considered preferable to plasma for rapid INR correction in many countries, 7, 13 something highlighted in treatment guidelines from a number of organizations, including the American College of Chest Physicians, the British Committee for Standards in Haematology and the Task Force for Advanced Bleeding Care in Trauma. 5, 6, 14 This prospective, randomized, multinational clinical trial compared 4F-PCC with plasma for urgent VKA reversal in patients with acute major bleeding.
Methods

Study design
This prospective, randomized, open-label, active-controlled, non-inferiority phase IIIb trial was conducted at 36 sites across USA and Europe. The study was sponsored by CSL Behring, registered at www.clinicaltrials.gov/ct2/show/NCT00708435 and performed in accordance with local ethics regulations; written informed consent was obtained from all patients.
Patients were randomly assigned (1:1) to receive either 4F-PCC (Beriplex® P/N, CSL Behring, Marburg, Germany) or plasma. Patients were assigned by a centrally managed biasedcoin minimization method, 15 which controlled for balance in number of patients among treatment arms overall and per site as well as among bleeding type (comprising: gastrointestinal (GI), visible, intracranial hemorrhage (ICH), musculoskeletal, and other non-visible bleeding). Study staff were not blinded to treatment allocation due to the inherent characteristics of the study drugs. Therefore, hemostatic efficacy was assessed by a blinded, independent Endpoint Adjudication Board (EAB). An independent Data Safety Monitoring Board (DSMB) reviewed
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Efficacy endpoints
Due to the complexity of assessing VKA reversal in a population experiencing diverse types of bleeding, the study was designed with two complementary co-primary endpoints. One co- 
Patients
Patients ( 18 years) receiving VKA therapy with an elevated INR ( 2.0 within 3 hours before study treatment) and experiencing an acute major bleeding event were eligible. Acute major bleeding was defined as one of the following: life-threatening or potentially life-threatening (according to the treating physician); acute bleeding associated with a fall in hemoglobin 2 g/dL; bleeding requiring blood product transfusion. Exclusion criteria are listed in Table 1 .
Treatment
On day 1, each patient received their assigned study treatment according to baseline INR and body weight ( Table 2) . 16 t tud ud udy y y tr tr trea eatm tm me en ent) t) ) an nd nd e e exp p per erie en nc n in in ing g g a an an a a acu cu ute te te m m maj aj ajo or r r b bl lee ee edi di ing ng ng e eve ve vent nt t w w wer er e e e el l lig igib ib ble le e. . Ac Ac Acu ut ute ma ma majo jor r r bleeding was s d d def ef e in in ned ed e a a as s s on n ne e e of of o t t the he he f f fol o o lo lo owi wi wing ng ng: : : li li ife fe e-t -t thr hr hrea eate te teni ni ning ng ng o o or r r po po ote te tent nt ntia ia iall ll lly y y li life fe fe-t -t thr hr hrea ea eatening interval.
All patients were to receive vitamin K by slow IV infusion dosed according to 2008 ACCP guidelines (5-10 mg) 17 or local clinical practice if different.
Assessments
Traditional trials for evaluating coagulation factor products (e.g. hemophilia treatments) are single-arm designs with subjective hemostasis endpoints. [18] [19] [20] To reduce potential investigator bias, and to increase endpoint objectivity, a hemostatic efficacy scale was developed in discussion with the FDA for adjudication by a blinded EAB. Hemostatic efficacy was rated by the EAB as "excellent", "good" or "poor/none". Effective hemostasis was defined as a rating of excellent or good over a 24-hour period from the start of infusion; non-effective was defined as a rating of poor/none. Data provided to the EAB for assessment included hemoglobin, hematocrit, any additional hemostatic treatments, AE data, and clinical outcome over the 24-hour assessment period. Objective pre-defined hemostasis criteria specific to each category of bleeding were used (supplementary table 3 ). Patients were assigned a poor/none hemostatic efficacy rating if their management required administration of any hemostatic products other than study product or packed red blood cells (PRBC) 24 hours of the start of study product infusion.
At the FDA's request, the time points used for assessment of the primary rating of hemostatic efficacy for patients with musculoskeletal or visible bleeding were modified (from 3 and 6 hours after the start of infusion to 1 and 4 hours after the end of infusion) during the study.
Re-consent was obtained from the majority of affected patients prior to the assessment of hemostatic efficacy. Two patients were assessed using the pre-amendment time points and, therefore, had missing data for the hemostatic efficacy endpoint. These patients were excluded from the intent-to-treat-efficacy (ITT-E) and per protocol (PP) analyses. The total volume and total infusion time of each study treatment were recorded. Blood samples were drawn for determination of INR and levels of VKDFs, PC, and PS prior to study product infusion and 0.5, 1, 3, 6, 12, and 24 hours after start of infusion, as well as INR at 0.5 hours after end of infusion. Additional hematology parameters (hemoglobin and platelet count)
were measured pre-infusion and 3 and 6 hours after start of infusion.
Baseline INR was assessed 3 hours before start of infusion. AEs and SAEs were recorded by study investigators. AEs and concomitant medications were recorded at every time point up to day 10 (visit window days 7-11); SAEs were recorded up to day 45 (visit window days 43-51).
Statistical analysis
Data were analyzed using SAS® (SAS Institute Inc.) v9. Following the protocol amendment to the hemostatic efficacy endpoint, target enrollment was increased to 212 to preserve study power. No power calculation was made for the INR endpoint measured at 0.5 hours after end of infusion.
Non-inferiority analyses were conducted on the ITT-E population via calculation of the two-sided 95% confidence interval (CI) for the difference in the proportions of patients with effective hemostasis and separately for the co-primary endpoint of INR reduction in the two treatment groups (4F-PCC minus plasma) using the method of Farrington-Manning. 21 Noninferiority of 4F-PCC was demonstrated if the lower limit of the 95% CI for the between-group
Data were analyzed using SAS® (SAS Institute Inc.) v9.1.3 and v9.2. Sample size was based on as ssu su ump mp mpti ti tion on ons s o o of e e eff ff ffec ective hemostasis for 85% in pa pa p t ti ients in the plas as a ma a g g gr ro roup and 90% in the 4F-P PCC C C group. It t wa was s or orig ig i in in nal al ally ly ly e e est stim im ma at ated ed d t t that (in nclu u ud di ing g a a a 1 10% 0% 0% d dro rop po pout ut r ra at te e) ) 92 92 92 p pat at atie ient nt n s s pe pe er r gr g gro o oup difference was greater than -10%. 4F-PCC would be successfully claimed non-inferior to plasma if non-inferiority was shown for both the hemostatic efficacy and INR reduction endpoints. If non-inferiority was shown, there would be an additional test for superiority of the effect of 4F-PCC compared with that of plasma for each of the co-primary endpoints. Superiority for an endpoint would be declared if the lower bound of the 95% CI exceeded zero. No adjustment to the type I error was required for this closed test procedure following the establishment of noninferiority.
The ITT population comprised all patients randomized to a treatment group. Table 3) .
Infusion durations, volumes and rates reflected the different study substances involved ( Table 4) .
Four patients in the 4F-PCC group and two in the plasma group did not receive vitamin K during the study. Eight patients in the 4F-PCC group and three in the plasma group received vitamin K by a non-IV route. The timings of vitamin K therapy in relation to study product infusion were comparable between groups (data not shown).
Most hematology variables were within the same ranges at baseline in both groups (data not shown). There was no difference between groups in the mean number of PRBC units transfused in the 24 hours after the start of infusion ( 1 . Baseline data and characteristics were i imi mi mila la lar r r be be betw tw twe e een n gr gr gro oups ( Table 3) . 
Hemostatic efficacy
Effective hemostasis (efficacy rating excellent or good) was achieved in 71 (72.4%) patients in the 4F-PCC group versus 68 (65.4%) in the plasma group ( (Figure 2a ). Furthermore, median INR was significantly lower in the 4F-PCC group compared with the plasma group until 12 hours after the start of infusion (Figure 2b) .
han other bleeding types (at 4 hours compared with 24 hours). In a post-hoc analy ysi s sis, s, s, sig ig igni ni nifi fi fica ca can ntly y more patients had effective hemostasis in the 4F-PCC group than the plasma group when visible an nd d d mu mu musc scul ul ulos os oske k le le eta ta tal l bleeding (rated at 4 hours) w w wer e e e e e analyzed (p= =0. 0 0 02 200 00 00) ) ) ( Table 6 ). In a post-hoc analysis, the 97.5% Farrington-Manning risk difference CIs for hemostatic efficacy and rapid INR reduction were also calculated assuming that the non-inferiority boundary was -10%. These 97.5% CIs are equivalent to testing each of the two endpoints at individual onesided levels of =0.0125. In this way, the multiplicity of testing for superiority in two co-primary endpoints was addressed preserving the type I error of a 0.025 significance level. For hemostatic efficacy, the 97.5% CI was (-7.6%, 21.7%). For rapid INR reduction, the 97.5% CI was (37.5%, 67.7%). The lower bound of this CI is greater than zero and, thus, superiority can be declared for 4F-PCC for the rapid INR reduction endpoint.
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Coagulation factor/protein levels
Mean pre-infusion levels of VKDFs, PC and PS were similar between groups (p-values >0.05).
Figure 3
shows changes in factor levels over time. Mean factor levels were significantly higher in the 4F-PCC group than the plasma group at 0.5, 1, 3, and 6 hours (p-values <0.05) apart from FVII at 6 hours (not significantly different between groups; p=0.19).
Results were similar for the co-primary endpoints when analyzed by country/region (supplementary tables 7, 8). Similar results were also seen for the ITT (supplementary tables 9, 10) and PP populations (data not shown).
Safety
Safety outcomes were assessed using the ITT-S population (Figure 1 ). There were 66/103 patients in the 4F-PCC group and 71/109 patients in the plasma group with 1 AE ( Table 8) .
AEs considered by investigators to be treatment-related were reported for 10 patients in the 4F- Thromboembolic AEs were reported during the study for eight patients in the 4F-PCC group and seven in the plasma group (Table 8) . Four patients in the 4F-PCC group and three patients in the plasma group had events considered treatment-related by investigators. There were five patients in the 4F-PCC group and three patients in the plasma group with serious thromboembolic events, which were reviewed by the SAB. The SAB adjudicated that two patients in the 4F-PCC group and two in the plasma group had serious thromboembolic events that were treatment-related. The SAB did not confirm one investigator-listed SAE of myocardial infarction (4F-PCC group) as a thromboembolic event.
Five patients (4.9%) in the 4F-PCC group had fluid overload and/or similar cardiac events ( 
Discussion
This was the first randomized clinical trial to compare 4F-PCC and plasma for urgent VKA reversal in patients with major bleeding. The study met the co-primary endpoints: 4F-PCC was non-inferior to plasma for hemostatic efficacy and for rapid INR reduction. Consistent with the rapid reduction in INR, mean plasma levels of VKDFs markedly increased to >60% at 0.5 hours after the start of 4F-PCC infusion, whereas increases in factor levels following administration of plasma were significantly slower. Between 3 and 24 hours (when vitamin K begins to take effect), factor levels in the plasma group trended toward those seen in the 4F-PCC group.
The rapid INR reduction and factor level increments are consistent with other studies demonstrating that PCCs are a clinically useful means to rapidly replace VKDFs and effectively lower INR. 16 (Table 6) .
Historically, clinical trials of hemostasis have had limitations, some of which were present in this trial. Commonly, trials with bleeding endpoints lack defined efficacy criteria or defined time points for analysis and most hemostatic efficacy scales have some subjective elements. In this trial, endpoints consistent with standard clinical assessments and time points were explicitly defined for the blinded EAB. This was the first clinical trial to use an EAB for this indication, which may explain why the frequency of hemostatic efficacy in this trial was different than anticipated based on other studies using non-standardized assessments. Another challenge in clinical bleeding trials is the inability to perform direct assessments of hemostasis (continuously and in real time) for many types of bleeding, such as GI hemorrhage. The timed nature of the assessments in this trial meant that actual hemostasis may have been achieved earlier than recorded.
The importance of the timing of assessments can also be seen for the rapid INR reversal reviewed all study deaths and adjudicated that one death (patient died at home with unknown cause, 7 days post-administration of 4F-PCC) was related to study product. There was no unifying pattern to the deaths except for the frequent finding of a high co-morbid burden, advanced age, and death after being placed on comfort care (12/15 patients).
Historically, the association of PCCs with thromboembolic events has been a concern.
Two recent comprehensive reviews, based on single-arm studies of PCCs, concluded that there is a low risk of thromboembolic events in patients treated with PCCs for VKA reversal and that underlying disease and dosing may be important factors in increasing risk. 13, 26 This study found no evidence of an increased thromboembolic risk associated with this 4F-PCC compared with plasma -thromboembolism might occur in this patient population due to underlying risks irrespective of the means used to reverse VKA. 27, 28 Fluid overload and similar cardiac events occurred relatively frequently after plasma transfusion for VKA reversal, as previously described. 7, 29 PCCs have several safety advantages compared with plasma with respect to rare but important AEs, many of which are not measurable in a trial such as this. Plasma transfusions are associated with allergic reactions, risk of TACO, TRALI and pathogen transmission; [30] [31] [32] [33] [34] however, several strategies have reduced many of these risks. 33 This study was not powered to assess the incidence of TRALI and therefore specific data are not available. PCCs undergo a series of pathogen-reduction and inactivation steps, and are associated with a minimal risk of pathogen transmission. 13, 26 The low infusion volume of PCCs avoids TACO; the median volume of plasma administered in this study was >8 times greater than the volume of 4F-PCC (813.5 mL vs 99.4 mL).
Overall, these results add to the existing evidence that 4F-PCC is an acceptable alternative to plasma for VKA reversal in time-and volume-critical situations. PCCs normalize the INR more plasma -thromboembolism might occur in this patient population due to underl ly yi ying ng g r ris is sks ks ks rrespective of the means used to reverse VKA. 27, 28 Fl rapidly than plasma, [35] [36] [37] [38] which has led to their widespread use for VKA reversal throughout Europe for >20 years. 12, 39 This preference for PCCs over plasma is reflected in many guidelines for VKA reversal. 5, 6, 14 
Conclusions
This was the first randomized, controlled study comparing PCC with plasma in patients receiving
VKAs who presented with acute major bleeding. The efficacy of 4F-PCC was demonstrated by clinical assessments of bleeding, and supported by laboratory measurements of INR and factor levels. The study showed that 4F-PCC is an effective alternative to plasma for the urgent reversal of VKA therapy in major bleeding events and that this 4F-PCC has an acceptable safety profile compared with plasma. oGlasgow coma score (GCS) <7 ‡ oIntracerebral hematoma volume >30 cc (assessed by ABC/2) oFor subdural hematomas: maximum thickness 10 mm, midline shift 5 mm oFor subarachnoid hemorrhage: any evidence of hydrocephalus oInfratentorial ICH location oEpidural hematomas oIntraventricular extension of hemorrhage oModified Rankin Scale >3 prior to ICH *Patients with acute major bleeding requiring minimally invasive procedures (e.g. endoscopy, bronchoscopy, central lines) that were indicated for diagnostic or therapeutic reasons were not excluded per protocol, as long as plasma was intended to be given for treatment of major bleeding †Exclusion added at time of amendment ‡Modified from GCS <9 to GCS <7 upon request of FDA Prior antiplatel el elet et et t t the he hera ra rapy py py ( (<2 <2 < w w wee ee eek ks be be befo fo ore re s s stu tu tudy dy dy e e ent nt ntry ry y); ); ); n n n ( ( (%) % % l id l ( ) ( ) *INR 1.3 at 0.5 h after the end of infusion; †4F-PCC non-inferior to plasma: lower limit of 95% CI >-10% Farrington-Manning p-value for non-inferiority p<0.0001 rejecting null hypothesis of inferiority of 4F-PCC; 4F-PCC superior to plasma: lower limit of 95% CI >0; 4F-PCC, four-factor prothrombin complex concentrate; CI, confidence interval Table 7 . Rapid INR reduction (ITT-E population). N= =98 98 98) plasma, whole blood cell pack, or coagulation factor products)
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